Global Infantile Spasm Treatment Market Growth (Status and Outlook) 2023-2029

Global Infantile Spasm Treatment Market Growth (Status and Outlook) 2023-2029

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

LPI (LP Information)' newest research report, the “Infantile Spasm Treatment Industry Forecast” looks at past sales and reviews total world Infantile Spasm Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Infantile Spasm Treatment sales for 2023 through 2029. With Infantile Spasm Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Infantile Spasm Treatment industry.

This Insight Report provides a comprehensive analysis of the global Infantile Spasm Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Infantile Spasm Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Infantile Spasm Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Infantile Spasm Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Infantile Spasm Treatment.

The global Infantile Spasm Treatment market size is projected to grow from US$ 136.9 million in 2022 to US$ 177 million in 2029; it is expected to grow at a CAGR of 3.7% from 2023 to 2029.

United States market for Infantile Spasm Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Infantile Spasm Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Infantile Spasm Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Infantile Spasm Treatment players cover Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma, Valerion Therapeutics, Catalyst Pharmaceuticals, Anavex Life Sciences, Retrophin and GW Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Infantile Spasm Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Oral
Parenteral

Segmentation by application
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.